Checkpoint blockade immunotherapy for cancer comes of age.
Vicki
V
Brower
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D016190:Carboplatin / Q000008:administration & dosage; D059447:Cell Cycle Checkpoints / Q000187:drug effects* / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D000077594:Nivolumab; D017239:Paclitaxel / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; D000077594:Nivolumab; D016190:Carboplatin; D017239:Paclitaxel; C520704:tremelimumab